Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib + Metronomic Capecitabine in HER2+ Advanced Breast Cancer
NCT03923166Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Apr 2019
- Primary completion
- Apr 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pyrotinib in breast cancer, sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Objective Response Rate at 4 months. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03923166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03923166.